Amylyx Pharmaceuticals Inc (AMLX) is a pioneering biopharmaceutical company dedicated to creating transformative therapies for neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company’s lead product candidate, AMX0035, features an innovative neuroprotective mechanism that has demonstrated promising results in enhancing patient outcomes. Backed by a strong clinical pipeline and a team of specialists in neurology, Amylyx is strategically positioned to address critical unmet medical needs, presenting a compelling investment opportunity for institutional investors interested in cutting-edge solutions for challenging neurological disorders.
| Revenue (TTM) | -665,000 |
| Gross Profit (TTM) | $-95.89M |
| EBITDA | $-158.80M |
| Operating Margin | 0.00% |
| Return on Equity | -63.30% |
| Return on Assets | -38.80% |
| Revenue/Share (TTM) | $-0.01 |
| Book Value | $2.46 |
| Price-to-Book | 7.44 |
| Price-to-Sales (TTM) | 0.66 |
| EV/Revenue | 6446.63 |
| EV/EBITDA | -11.71 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -99.60% |
| Shares Outstanding | $111.19M |
| Float | $83.53M |
| % Insiders | 7.92% |
| % Institutions | 105.33% |
Volatility is currently contracting
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026.
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Amylyx Pharmaceuticals NASDAQ: AMLX is preparing for a pivotal Phase 3 readout for AVEXITIDE, its lead asset for post-bariatric hypoglycemia, or PBH, with data from the LUCIDITY trial expected in the third quarter, Co-Chief Executive Officer Joshua Cohen said at the BofA Annual Healthcare Conference.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the launch of a U.S. Expanded Access Program (EAP) for up to 250 adults with post-bariatric hypoglycemia (PBH) to provide treatment access to avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. The EAP allows U.S. physicians to request avexitide for adults with PBH following Roux-en-Y gastric bypass (RYGB) surgery who have a se.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference.
